Loss of cyclin-dependent kinase-like 2 predicts poor prognosis in gastric cancer, and its overexpression suppresses cells growth and invasion

Chia Lang Fang, Yih Huei Uen, Han Kun Chen, You Cheng Hseu, Chih Chan Lin, Shih Ting Hung, Ding Ping Sun, Kai Yuan Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cyclin-dependent kinase-like 2 (CDKL2), a new member of the cyclin-dependent kinase family, may be involved in gastric cancer (GC) progression. Thus, we conducted this study to explore the clinical effect of CDKL2 in GC. Immunohistochemistry was used to measure CDKL2 levels in gastric tissues. The association of a high CDKL2 level with clinical and pathological characteristics, and the correlation between the CDKL2 level and disease-free and overall survival were analyzed. Transfection was employed to overexpress CDKL2 in GC cells and to investigate the effect of CDKL2 overexpression on cell proliferation and invasion. Loss of CDKL2 was positively correlated with several clinical and pathological characteristics, and patients with a low CDKL2 level had significantly poorer disease-free and overall survival than those with a high level (P =.005 and.001, respectively). Univariate analysis using the Cox proportional hazards model indicated that a low CDKL2 level was a prognosticator for inferior disease-free survival (P =.007). Based on immmunoblotting data, AGS and HGC-27 GC cells were chosen for CDKL2 overexpression. Cellular studies revealed that CDKL2 overexpression impaired cell proliferation and invasion. Loss of CDKL2 may serve as a biomarker for predicting GC patient outcomes and a potential therapeutic target for GC treatment.

Original languageEnglish
Pages (from-to)2993-3002
Number of pages10
JournalCancer Medicine
Volume7
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Cyclin-Dependent Kinase 2
Stomach Neoplasms
Growth
Disease-Free Survival
Cell Proliferation
Cyclin-Dependent Kinases
Proportional Hazards Models

Keywords

  • CDKL2
  • gastric cancer
  • immunohistochemistry
  • prognosis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Loss of cyclin-dependent kinase-like 2 predicts poor prognosis in gastric cancer, and its overexpression suppresses cells growth and invasion. / Fang, Chia Lang; Uen, Yih Huei; Chen, Han Kun; Hseu, You Cheng; Lin, Chih Chan; Hung, Shih Ting; Sun, Ding Ping; Lin, Kai Yuan.

In: Cancer Medicine, Vol. 7, No. 7, 01.07.2018, p. 2993-3002.

Research output: Contribution to journalArticle

Fang, Chia Lang ; Uen, Yih Huei ; Chen, Han Kun ; Hseu, You Cheng ; Lin, Chih Chan ; Hung, Shih Ting ; Sun, Ding Ping ; Lin, Kai Yuan. / Loss of cyclin-dependent kinase-like 2 predicts poor prognosis in gastric cancer, and its overexpression suppresses cells growth and invasion. In: Cancer Medicine. 2018 ; Vol. 7, No. 7. pp. 2993-3002.
@article{9951b3fc169a40929fc33f981b4b6f50,
title = "Loss of cyclin-dependent kinase-like 2 predicts poor prognosis in gastric cancer, and its overexpression suppresses cells growth and invasion",
abstract = "Cyclin-dependent kinase-like 2 (CDKL2), a new member of the cyclin-dependent kinase family, may be involved in gastric cancer (GC) progression. Thus, we conducted this study to explore the clinical effect of CDKL2 in GC. Immunohistochemistry was used to measure CDKL2 levels in gastric tissues. The association of a high CDKL2 level with clinical and pathological characteristics, and the correlation between the CDKL2 level and disease-free and overall survival were analyzed. Transfection was employed to overexpress CDKL2 in GC cells and to investigate the effect of CDKL2 overexpression on cell proliferation and invasion. Loss of CDKL2 was positively correlated with several clinical and pathological characteristics, and patients with a low CDKL2 level had significantly poorer disease-free and overall survival than those with a high level (P =.005 and.001, respectively). Univariate analysis using the Cox proportional hazards model indicated that a low CDKL2 level was a prognosticator for inferior disease-free survival (P =.007). Based on immmunoblotting data, AGS and HGC-27 GC cells were chosen for CDKL2 overexpression. Cellular studies revealed that CDKL2 overexpression impaired cell proliferation and invasion. Loss of CDKL2 may serve as a biomarker for predicting GC patient outcomes and a potential therapeutic target for GC treatment.",
keywords = "CDKL2, gastric cancer, immunohistochemistry, prognosis",
author = "Fang, {Chia Lang} and Uen, {Yih Huei} and Chen, {Han Kun} and Hseu, {You Cheng} and Lin, {Chih Chan} and Hung, {Shih Ting} and Sun, {Ding Ping} and Lin, {Kai Yuan}",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/cam4.1577",
language = "English",
volume = "7",
pages = "2993--3002",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Loss of cyclin-dependent kinase-like 2 predicts poor prognosis in gastric cancer, and its overexpression suppresses cells growth and invasion

AU - Fang, Chia Lang

AU - Uen, Yih Huei

AU - Chen, Han Kun

AU - Hseu, You Cheng

AU - Lin, Chih Chan

AU - Hung, Shih Ting

AU - Sun, Ding Ping

AU - Lin, Kai Yuan

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Cyclin-dependent kinase-like 2 (CDKL2), a new member of the cyclin-dependent kinase family, may be involved in gastric cancer (GC) progression. Thus, we conducted this study to explore the clinical effect of CDKL2 in GC. Immunohistochemistry was used to measure CDKL2 levels in gastric tissues. The association of a high CDKL2 level with clinical and pathological characteristics, and the correlation between the CDKL2 level and disease-free and overall survival were analyzed. Transfection was employed to overexpress CDKL2 in GC cells and to investigate the effect of CDKL2 overexpression on cell proliferation and invasion. Loss of CDKL2 was positively correlated with several clinical and pathological characteristics, and patients with a low CDKL2 level had significantly poorer disease-free and overall survival than those with a high level (P =.005 and.001, respectively). Univariate analysis using the Cox proportional hazards model indicated that a low CDKL2 level was a prognosticator for inferior disease-free survival (P =.007). Based on immmunoblotting data, AGS and HGC-27 GC cells were chosen for CDKL2 overexpression. Cellular studies revealed that CDKL2 overexpression impaired cell proliferation and invasion. Loss of CDKL2 may serve as a biomarker for predicting GC patient outcomes and a potential therapeutic target for GC treatment.

AB - Cyclin-dependent kinase-like 2 (CDKL2), a new member of the cyclin-dependent kinase family, may be involved in gastric cancer (GC) progression. Thus, we conducted this study to explore the clinical effect of CDKL2 in GC. Immunohistochemistry was used to measure CDKL2 levels in gastric tissues. The association of a high CDKL2 level with clinical and pathological characteristics, and the correlation between the CDKL2 level and disease-free and overall survival were analyzed. Transfection was employed to overexpress CDKL2 in GC cells and to investigate the effect of CDKL2 overexpression on cell proliferation and invasion. Loss of CDKL2 was positively correlated with several clinical and pathological characteristics, and patients with a low CDKL2 level had significantly poorer disease-free and overall survival than those with a high level (P =.005 and.001, respectively). Univariate analysis using the Cox proportional hazards model indicated that a low CDKL2 level was a prognosticator for inferior disease-free survival (P =.007). Based on immmunoblotting data, AGS and HGC-27 GC cells were chosen for CDKL2 overexpression. Cellular studies revealed that CDKL2 overexpression impaired cell proliferation and invasion. Loss of CDKL2 may serve as a biomarker for predicting GC patient outcomes and a potential therapeutic target for GC treatment.

KW - CDKL2

KW - gastric cancer

KW - immunohistochemistry

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85047537438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047537438&partnerID=8YFLogxK

U2 - 10.1002/cam4.1577

DO - 10.1002/cam4.1577

M3 - Article

AN - SCOPUS:85047537438

VL - 7

SP - 2993

EP - 3002

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 7

ER -